NCT05833763: An ongoing trial by Australasian Leukaemia and Lymphoma Group
This trial is ongoing. It must report results 7 years, 4 months from now.
Full data
| Full entry on ClinicalTrials.gov | NCT05833763 |
|---|---|
| Title | An Open-label, Single-arm, Phase 2 Trial of GlOfitamab anD pIrtobrutinib (LOXo-305) in Patients With Mantle Cell Lymphoma and Prior Exposure to a BTK Inhibitor |
| Results Status | Ongoing |
| ACT or pACT? | This is what FDAAA officially calls an "Applicable Clinical Trial" |
| Start date | Oct. 12, 2023 |
| Completion date | April 30, 2032 |
| Required reporting date | April 30, 2033, midnight |
| Actual reporting date | None |
| Date last checked at ClinicalTrials.gov | Dec. 12, 2025 |
| Days late | None |